Lakewood-Amedex Biotherapeutics Inc.
LABT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LABT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LABT
Lakewood-Amedex Biotherapeutics Inc. (LABT) is a clinical-stage biopharmaceutical company focused on developing its lead antimicrobial candidate Nu-3, having recently strengthened its balance sheet through a Series C financing and Nasdaq listing, though it remains pre-revenue and requires additional capital to complete development.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Lakewood-Amedex Biotherapeutics Inc. (LABT) is a clinical-stage biopharmaceutical company focused on developing its lead antimicrobial candidate Nu-3, having recently strengthened its balance sheet through a Series C financing and Nasdaq listing, though it remains pre-revenue and requires additional capital to complete development.
- Lead product candidate Nu-3 is being advanced toward a Phase 2a dose-comparison clinical study [sec_mda · as of 2026-08-14].
- Completed a Series C Convertible Preferred Stock financing in Q2 2026, generating approximately $7.5 million in gross proceeds [sec_mda · as of 2026-08-14].
- Listed its common stock on the Nasdaq Capital Market during the quarter ended June 30, 2026 [sec_mda · as of 2026-08-14].
- As of June 30, 2026, the company held cash, cash equivalents, and certificates of deposit sufficient to support near-term operating objectives of less than 12 months [sec_mda · as of 2026-08-14].
- The company has incurred recurring operating losses since inception and expects to continue incurring losses as it advances clinical development [sec_mda · as of 2026-08-14].
What works
- The company substantially improved its liquidity and working capital position during the six months ended June 30, 2026, primarily through the Series C financing and conversion of preferred stock and convertible debt into common stock [sec_mda · as of 2026-08-14].
- The Nasdaq listing and simplified capital structure position the company to advance its clinical development plans [sec_mda · as of 2026-08-14].
- The company employs an outsourced model for manufacturing and clinical activities, which management believes enables capital efficiency and focus on pipeline advancement [sec · filed 2026-05-01].
What to weigh
- The company has no approved products and has not generated any revenue from product sales [sec · filed 2026-05-01].
- As of June 30, 2026, the company had cash and equivalents of $2.6 million and a net loss of $3.8 million for the period, with shareholders' equity of only $0.4 million [latest reported financials].
- Management expects that additional capital will be required to complete clinical development, pursue regulatory approvals, and support commercialization activities [sec_mda · as of 2026-08-14].
- The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern [sec · filed 2026-05-01].
From the filings
Quoted directly from source documents.
The company completed a Series C financing and Nasdaq listing in Q2 2026, strengthening its balance sheet.
“During the quarter, the Company completed a private placement of its Series C Convertible Preferred Stock, generating approximately $7.5 million in gross proceeds, completed the listing of its common stock on the Nasdaq Capital Market, and substantially simplified its capital structure through the conversion of its outstanding preferred stock and convertible debt into common stock.”
SEC MD&A · August 14, 2026
The company has incurred recurring operating losses since inception.
“The Company has incurred recurring operating losses since inception and expects to continue incurring losses as it advances the clinical development of Nu-3 and its other product candidates.”
SEC MD&A · August 14, 2026
The company's auditors have raised substantial doubt about its ability to continue as a going concern.
“ited financial statements for the years ended December 31, 2025 and 2024 include an explanatory paragraph from our independent registered public accounting firm stating that our recurring losses from operations raise substantial doubt about our ability to continue as a going concern.”
SEC filings · May 1, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses [sec · filed 2026-05-01].
- Need for additional capital — Management expects additional capital will be required to complete clinical development and pursue regulatory approvals [sec_mda · as of 2026-08-14].
- No revenue or approved products — The company has no products approved for commercial sale and has not generated any revenue from product sales [sec · filed 2026-05-01].
- Clinical development risks — Nu-3 is still in early clinical stages; Phase 2a study has not yet commenced and outcomes are uncertain [sec_mda · as of 2026-08-14].
What to watch
- Initiation and results of the Phase 2a dose-comparison clinical study for Nu-3 [sec_mda · as of 2026-08-14].
- Ability to secure additional financing to extend cash runway beyond the current 12-month estimate [sec_mda · as of 2026-08-14].
- Progress in preclinical development of additional pipeline candidates and any IND filings [sec · filed 2026-05-01].
- Any updates on the company's ability to generate revenue or enter into collaborations [sec · filed 2026-05-01].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Lakewood-Amedex Biotherapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lakewood-Amedex Biotherapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
6.5 months
D/E 0.15 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Lakewood-Amedex Biotherapeutics Inc.?
Lakewood-Amedex Biotherapeutics Inc. (LABT) is a clinical-stage biopharmaceutical company focused on developing its lead antimicrobial candidate Nu-3, having recently strengthened its balance sheet through a Series C financing and Nasdaq listing, though it remains pre-revenue and requires additional capital to complete development.
Who is the CEO of Lakewood-Amedex Biotherapeutics Inc.?
Dr. Kelvin Cooper Ph.D. is the chief executive officer of Lakewood-Amedex Biotherapeutics Inc. (LABT).
Where is Lakewood-Amedex Biotherapeutics Inc. headquartered?
Lakewood-Amedex Biotherapeutics Inc. (LABT) is headquartered in University Park, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.